A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC.

Trial Profile

A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms MILES-4
  • Most Recent Events

    • 05 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 12 Sep 2017 Results of pooled data from two trials (MILES-3 and MILES-4) assessing quality of life (QOL) of adding cisplatin to single-agent first line chemotherapy in elderly patients with advanced non-small cell lung cancer, were presented at the 42nd European Society for Medical Oncology Congress.
    • 14 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top